Trial Profile
A Randomized, Open Label, Phase III Study of Overall Survival Comparing Pembrolizumab (MK-3475) versus Platinum Based Chemotherapy in Treatment Naïve Subjects with PD-L1 Positive Advanced or Metastatic Non-Small Cell Lung Cancer (Keynote 042)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 20 Feb 2024
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Carboplatin; Paclitaxel; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms KEYNOTE-042
- Sponsors Merck Sharp & Dohme; Merck Sharp & Dohme Corp.
- 06 Oct 2023 Time frame of primary endpoints has been changed from 38 months to upto approximately 44 months.
- 25 Jan 2023 Results of a retrospective exploratory analysis assessing prevalence of tTMB and STK11, KEAP1, and KRAS mutations determined by whole-exome sequencing of tumor tissue and matched normal DNA and their associations with outcomes published in the Annals of Oncology
- 28 Oct 2022 Results assessing Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non-Small-Cell Lung Cancer published in the Journal of Clinical Oncology